Iberdomide
| Clinical data | |
|---|---|
| Trade names | Zenbexus |
| Other names | CC-220 |
| AHFS/Drugs.com | zenbexus |
| License data |
|
| Routes of administration | By mouth |
| Drug class | Cereblon-modulating protein degrader |
| ATC code |
|
| Legal status | |
| Legal status |
|
| Identifiers | |
| |
| CAS Number |
|
| PubChem CID | |
| IUPHAR/BPS | |
| DrugBank | |
| ChemSpider | |
| UNII |
|
| KEGG | |
| ChEMBL | |
| Chemical and physical data | |
| Formula | C25H27N3O5 |
| Molar mass | 449.507 g·mol−1 |
| 3D model (JSmol) | |
| |
| |
Iberdomide, sold under the brand name Zenbexus, is an anti-cancer medication used for the treatment of multiple myeloma. It is a cereblon-modulating protein degrader and a thalidomide analog.. It is taken by mouth.
Iberdomide was approved for medical use in the United States in August 2026.
Category:
- Drugs not assigned an ATC code